A phase I study of IBI3016
Latest Information Update: 30 Mar 2024
At a glance
- Drugs IBI 3016 (Primary)
- Indications Hypertension
- Focus Therapeutic Use
Most Recent Events
- 30 Mar 2024 New trial record
- 20 Mar 2024 According to an Innovent Biologics media release, the company plans to initiate this trial in collaboration of SanageneBio in 2024.